Transcatheter embolization therapy in liver cancer: an update of clinical evidences.
暂无分享,去创建一个
[1] Myeong-Jin Kim,et al. Prognostic role of magnetic resonance imaging vs. computed tomography for hepatocellular carcinoma undergoing chemoembolization , 2015, Liver international : official journal of the International Association for the Study of the Liver.
[2] M. Pompili,et al. Single hepatocellular carcinoma smaller than 2 cm: are ethanol injection and radiofrequency ablation equally effective? , 2015, Anticancer research.
[3] M. Ducreux,et al. Predisposing Factors of Liver Necrosis after Transcatheter Arterial Chemoembolization in Liver Metastases from Neuroendocrine Tumor , 2015, CardioVascular and Interventional Radiology.
[4] S. Rose,et al. Yttrium-90 Resin Microsphere Radioembolization Using an Antireflux Catheter: An Alternative to Traditional Coil Embolization for Nontarget Protection , 2015, CardioVascular and Interventional Radiology.
[5] S. Kalva,et al. Drug-eluting beads , 2014 .
[6] B. Sangro. Chemoembolization and radioembolization. , 2014, Best practice & research. Clinical gastroenterology.
[7] D. Perkov,et al. Fluorouracil, Leucovorin and Irinotecan Combined with Intra-Arterial Hepatic Infusion of Drug-Eluting Beads Preloaded with Irinotecan in Unresectable Colorectal Liver Metastases: Side Effects and Results of a Concomitant Treatment Schedule. Clinical Investigation , 2014, Tumori.
[8] Chenhui Lu,et al. Does Drug-Eluting Bead Transcatheter Arterial Chemoembolization Improve the Management of Patients with Hepatocellular Carcinoma? A Meta-Analysis , 2014, PloS one.
[9] K. Yoshimitsu. Transarterial chemoembolization using iodized oil for unresectable hepatocellular carcinoma: perspective from multistep hepatocarcinogenesis , 2014, Hepatic medicine : evidence and research.
[10] C. Bartolozzi,et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma , 2014, British Journal of Cancer.
[11] M. Sherman. Staging for hepatocellular carcinoma: complex and confusing. , 2014, Gastroenterology.
[12] S. Fan,et al. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. , 2014, Gastroenterology.
[13] A. Ahuja,et al. Acoustic Radiation Force Impulse Elastography for Efficacy Evaluation after Hepatocellular Carcinoma Radiofrequency Ablation: A Comparative Study with Contrast-Enhanced Ultrasound , 2014, BioMed research international.
[14] Daniel B Vigneron,et al. Kinetic and perfusion modeling of hyperpolarized (13)C pyruvate and urea in cancer with arbitrary RF flip angles. , 2014, Quantitative imaging in medicine and surgery.
[15] F. Gao,et al. Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: an up-to-date meta-analysis , 2014, Tumor Biology.
[16] H. Kitajima,et al. Apparent diffusion coefficient quantification as an early imaging biomarker of response and predictor of survival following yttrium-90 radioembolization for unresectable infiltrative hepatocellular carcinoma with portal vein thrombosis , 2014, Abdominal Imaging.
[17] M. Mulcahy,et al. Perfusion reduction at transcatheter intraarterial perfusion MR imaging: a promising intraprocedural biomarker to predict transplant-free survival during chemoembolization of hepatocellular carcinoma. , 2014, Radiology.
[18] M. Salvatore,et al. Diagnostic accuracy of MR imaging to identify and characterize focal liver lesions: comparison between gadolinium and superparamagnetic iron oxide contrast media. , 2014, Quantitative imaging in medicine and surgery.
[19] L. Bédouet,et al. Poly(ethylene glycol) methacrylate hydrolyzable microspheres for transient vascular embolization. , 2014, Acta biomaterialia.
[20] D. Dupuy,et al. Thermal ablation of tumours: biological mechanisms and advances in therapy , 2014, Nature Reviews Cancer.
[21] Y. Kim,et al. Small single-nodule hepatocellular carcinoma: comparison of transarterial chemoembolization, radiofrequency ablation, and hepatic resection by using inverse probability weighting. , 2014, Radiology.
[22] B. Guiu,et al. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review. , 2013, Critical reviews in oncology/hematology.
[23] A. K. Poyraz,et al. The role of diffusion weighted magnetic resonance imaging in oncologic settings. , 2013, Quantitative imaging in medicine and surgery.
[24] David Cosgrove,et al. Intrahepatic cholangiocarcinoma: management options and emerging therapies. , 2013, Journal of the American College of Surgeons.
[25] P. Invernizzi. Liver auto-immunology: the paradox of autoimmunity in a tolerogenic organ. , 2013, Journal of autoimmunity.
[26] Hirokazu Takahashi,et al. Survival advantage of radiofrequency ablation for hepatocellular carcinoma: comparison with ethanol injection. , 2013, Hepato-gastroenterology.
[27] R. Loffroy,et al. C-arm dual-phase cone-beam CT: a revolutionary real-time imaging modality to assess drug-eluting beads TACE success in liver cancer patients. , 2013, Quantitative imaging in medicine and surgery.
[28] L. Bolondi,et al. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. , 2013, Journal of hepatology.
[29] Marek Ancukiewicz,et al. Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy , 2013, Journal of Hematology & Oncology.
[30] Yao-ting Chen,et al. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. , 2013, World journal of gastroenterology.
[31] G. Otto,et al. Comparison of resection and transarterial chemoembolisation in the treatment of advanced intrahepatic cholangiocarcinoma--a single-center experience. , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[32] A. Julianov. Radiofrequency ablation or resection for small colorectal liver metastases - a plea for caution. , 2013, Quantitative imaging in medicine and surgery.
[33] Z. Ren,et al. Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis , 2013, BMC Gastroenterology.
[34] Sang Joon Park,et al. Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an Asian cooperative study between Japan and Korea. , 2013, Journal of vascular and interventional radiology : JVIR.
[35] S. Raman,et al. Complete tumor encapsulation on magnetic resonance imaging: A potentially useful imaging biomarker for better survival in solitary large hepatocellular carcinoma , 2013, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[36] Myeong Jun Song,et al. 18F-Fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[37] S. Zangos,et al. Repetitive transarterial chemoembolization (TACE) of liver metastases from gastric cancer: local control and survival results. , 2013, European journal of radiology.
[38] A. Zhu,et al. Combining transarterial chemoembolization with radiofrequency ablation for hepatocellular carcinoma: one step forward? , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] W. Lau,et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] Haiyang Xie,et al. Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis. , 2013, Hepato-gastroenterology.
[41] R. de Bree. Functional imaging to predict treatment response after (chemo) radiotherapy of head and neck squamous cell carcinoma. , 2013, Quantitative imaging in medicine and surgery.
[42] S. Rose,et al. Downstream Hepatic Arterial Blood Pressure Changes Caused by Deployment of the Surefire AntiReflux Expandable Tip , 2013, CardioVascular and Interventional Radiology.
[43] T. Pawlik,et al. Phase II Study of Chemoembolization With Drug-Eluting Beads in Patients With Hepatic Neuroendocrine Metastases: High Incidence of Biliary Injury , 2013, CardioVascular and Interventional Radiology.
[44] Jing Yuan,et al. Quantitative evaluation of dual-flip-angle T1 mapping on DCE-MRI kinetic parameter estimation in head and neck. , 2012, Quantitative imaging in medicine and surgery.
[45] Yi-Xiang J Wang. Transcatheter Embolization Therapy in Liver Cancer , 2012 .
[46] L. Roberts,et al. Immunotherapeutic Approaches to Hepatocellular Carcinoma Treatment , 2012, Liver Cancer.
[47] J. Trojan,et al. Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success , 2012, International journal of cancer.
[48] Jürgen K Willmann,et al. Ultrasound for molecular imaging and therapy in cancer. , 2012, Quantitative imaging in medicine and surgery.
[49] M. Makuuchi,et al. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. , 2012, Journal of hepatology.
[50] D. Chan,et al. Superselective transarterial chemoembolization vs hepatic resection for resectable early-stage hepatocellular carcinoma in patients with Child-Pugh class a liver function. , 2012, European journal of radiology.
[51] T. de Baère,et al. Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. , 2012, Journal of hepatology.
[52] N. Lepareur,et al. 188Re-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside , 2012, International journal of molecular imaging.
[53] Y. Shin,et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. , 2012, Radiology.
[54] J. Bruix,et al. Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] Tim Meyer,et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. , 2011, Journal of hepatology.
[56] T. Vogl,et al. Liver Metastases of Pancreatic Cancer: Role of Repetitive Transarterial Chemoembolization (TACE) on Tumor Response and Survival , 2011, Pancreas.
[57] C. Bartolozzi,et al. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. , 2011, Journal of vascular and interventional radiology : JVIR.
[58] T. Pawlik,et al. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] T. Vogl,et al. Transcatheter Treatment of Hepatocellular Carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): Technical Recommendations , 2011, CardioVascular and Interventional Radiology.
[60] K. Leung,et al. Chemoembolization agents for cancer treatment. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[61] F. Izzo,et al. Survival after yttrium‐90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation , 2011, Hepatology.
[62] M. Makuuchi,et al. Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version , 2011, Digestive Diseases.
[63] T. George,et al. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma , 2011, Alimentary pharmacology & therapeutics.
[64] H. El‐Serag,et al. Risk factors for cholangiocarcinoma , 2011, Hepatology.
[65] V. Esposito,et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. , 2011, Anticancer research.
[66] Chia-Yang Hsu,et al. Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: A propensity score analysis , 2011, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[67] V. Mazzaferro,et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. , 2011, Cancer treatment reviews.
[68] Ben Lawrence,et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. , 2011, Endocrinology and metabolism clinics of North America.
[69] O. Matsui,et al. Prolonged recurrence‐free survival following OK432‐stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization , 2011, Clinical and experimental immunology.
[70] A. Benson,et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. , 2011, Gastroenterology.
[71] T. Vogl,et al. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. , 2010, AJR. American journal of roentgenology.
[72] T. Walker. Transarterial Chemoembolization Can Be Safely Performed in Patients with Hepatocellular Carcinoma Invading the Main Portal Vein and May Improve the Overall Survival , 2011 .
[73] W. Lau,et al. Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Prospective Comparative Study , 2011, Annals of Surgical Oncology.
[74] C. Mathers,et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.
[75] Yoshiyuki Suzuki,et al. New classification of dynamic computed tomography images predictive of malignant characteristics of hepatocellular carcinoma , 2010, Hepatology research : the official journal of the Japan Society of Hepatology.
[76] T. de Baère,et al. Comparative study of chemoembolization loadable beads: in vitro drug release and physical properties of DC bead and hepasphere loaded with doxorubicin and irinotecan. , 2010, Journal of vascular and interventional radiology : JVIR.
[77] M. Abecassis,et al. Comparative effectiveness of radioembolization and the standard of care for hepatocellular carcinoma: Is a randomized survival study feasible? , 2010 .
[78] J. Bruix,et al. Ablation for hepatocellular carcinoma: Is there need to have a winning technique? , 2010, Journal of hepatology.
[79] Riccardo Lencioni,et al. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.
[80] S. Schoenberg,et al. Application of DC Beads in Hepatocellular Carcinoma: Clinical and Radiological Results of a Drug Delivery Device for Transcatheter Superselective Arterial Embolization , 2010, Oncology Research and Treatment.
[81] A. Benson,et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. , 2010, Gastroenterology.
[82] Y. Rolland,et al. Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides , 2010, Nature Reviews Gastroenterology &Hepatology.
[83] F. Orsi,et al. Bland Embolization in Patients with Unresectable Hepatocellular Carcinoma Using Precise, Tightly Size-Calibrated, Anti-Inflammatory Microparticles: First Clinical Experience and One-Year Follow-Up , 2010, CardioVascular and Interventional Radiology.
[84] Anastasia Pomoni,et al. Prospective Randomized Comparison of Chemoembolization with Doxorubicin-Eluting Beads and Bland Embolization with BeadBlock for Hepatocellular Carcinoma , 2010, CardioVascular and Interventional Radiology.
[85] T. Vogl,et al. Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. , 2009, European journal of radiology.
[86] T. Vogl,et al. Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study , 2009, CardioVascular and Interventional Radiology.
[87] T. Vogl,et al. Liver metastases of neuroendocrine tumors: treatment with hepatic transarterial chemotherapy using two therapeutic protocols. , 2009, AJR. American journal of roentgenology.
[88] Sung W. Shin. The Current Practice of Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma , 2009, Korean journal of radiology.
[89] C. Shields,et al. High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma. , 2009, Radiology.
[90] T. Okusaka,et al. A randomized phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in comparison with zinostatin stimalamer in patients with hepatocellular carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] H. Kauczor,et al. Analysis of Nontarget Embolization Mechanisms During Embolization and Chemoembolization Procedures , 2009, CardioVascular and Interventional Radiology.
[92] Jordi Rimola,et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma , 2009, Cancer.
[93] K. Eichler,et al. Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. , 2009, Radiology.
[94] S. Goldberg,et al. Optimal strategies for combining transcatheter arterial chemoembolization and radiofrequency ablation in rabbit VX2 hepatic tumors. , 2008, Journal of vascular and interventional radiology : JVIR.
[95] J. Dufour,et al. Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease , 2008, Expert review of anticancer therapy.
[96] B. Sangro,et al. Comparative study of four different spherical embolic particles in an animal model: a morphologic and histologic evaluation. , 2008, Journal of vascular and interventional radiology : JVIR.
[97] K. Malagari. Drug-eluting particles in the treatment of HCC: chemoembolization with doxorubicin-loaded DC Bead™ , 2008, Expert review of anticancer therapy.
[98] J. H. Kim,et al. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients , 2008, Cancer science.
[99] S. Vaidya,et al. An Overview of Embolic Agents , 2008, Seminars in interventional radiology.
[100] P. Quaretti,et al. Transarterial Chemoembolization for Hepatocellular Carcinoma with Drug-Eluting Microspheres: Preliminary Results from an Italian Multicentre Study , 2008, CardioVascular and Interventional Radiology.
[101] D. Madoff,et al. Liver Anatomy: Microcirculation of the Liver , 2008, Seminars in interventional radiology.
[102] F. Farinati,et al. Transcatheter Arterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC): The Role of Angiogenesis and Invasiveness , 2008, The American Journal of Gastroenterology.
[103] M. Mulcahy,et al. Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. , 2008, World journal of gastroenterology.
[104] A. Lloyd,et al. Doxorubicin eluting beads—2: methods for evaluating drug elution and in-vitro:in-vivo correlation , 2008, Journal of materials science. Materials in medicine.
[105] A. Benson,et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis , 2007, Hepatology.
[106] Luigi Solbiati,et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? , 2007, Hepatology.
[107] D. Bluemke,et al. Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. , 2008, AJR. American journal of roentgenology.
[108] J. Kettenbach,et al. Drug-Loaded Microspheres for the Treatment of Liver Cancer: Review of Current Results , 2008, CardioVascular and Interventional Radiology.
[109] J. Jeong,et al. Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-sponsored multination study. , 2007, International journal of radiation oncology, biology, physics.
[110] C. Bordi,et al. Prognostic Factors in Gastrointestinal Endocrine Tumors , 2007, Endocrine pathology.
[111] M. Manns,et al. Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival. , 2007, Hepatobiliary & pancreatic diseases international : HBPD INT.
[112] A. Lloyd,et al. Doxorubicin eluting beads − 1: Effects of drug loading on bead characteristics and drug distribution , 2007, Journal of materials science. Materials in medicine.
[113] D. Srivastava,et al. Inoperable hepatocellular carcinoma: transarterial 188Re HDD-labeled iodized oil for treatment--prospective multicenter clinical trial. , 2007, Radiology.
[114] J. Chung,et al. Local Recurrence of Hepatocellular Carcinoma after Segmental Transarterial Chemoembolization: Risk Estimates Based on Multiple Prognostic Factors , 2007, Korean journal of radiology.
[115] S. Gulec,et al. Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: The tumor selectivity of the treatment as a function of tumor to liver flow ratio , 2007, Journal of Translational Medicine.
[116] B. Kang,et al. Transcatheter arterial chemoembolization of hepatocellular carcinoma with hepatic arteriovenous shunt after temporary balloon occlusion of hepatic vein. , 2007, Journal of vascular and interventional radiology : JVIR.
[117] J. Bruix,et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. , 2007, Journal of hepatology.
[118] S. Goldberg,et al. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. , 2007, Journal of vascular and interventional radiology : JVIR.
[119] A. Lewis,et al. Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[120] S. Zangos,et al. Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update , 2007, European Radiology.
[121] E. Cholongitas,et al. Transarterial Therapy for Hepatocellular Carcinoma: Which Technique Is More Effective? A Systematic Review of Cohort and Randomized Studies , 2007, CardioVascular and Interventional Radiology.
[122] A. Lewis,et al. Evaluation of irinotecan drug-eluting beads: a new drug-device combination product for the chemoembolization of hepatic metastases. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[123] K. Hong,et al. New Intra-arterial Drug Delivery System for the Treatment of Liver Cancer: Preclinical Assessment in a Rabbit Model of Liver Cancer , 2006, Clinical Cancer Research.
[124] W. Lau,et al. A Prospective Randomized Trial Comparing Percutaneous Local Ablative Therapy and Partial Hepatectomy for Small Hepatocellular Carcinoma , 2006, Annals of surgery.
[125] J. Dumortier,et al. Unresectable hepatocellular carcinoma: survival and prognostic factors after lipiodol chemoembolisation in 89 patients. , 2006, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[126] A. Lloyd,et al. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. , 2006, Journal of vascular and interventional radiology : JVIR.
[127] W. Chapman,et al. Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents. , 2005, Journal of vascular and interventional radiology : JVIR.
[128] J. Bruix,et al. Management of hepatocellular carcinoma , 2005, Hepatology.
[129] M. Choti,et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. , 2005, Journal of vascular and interventional radiology : JVIR.
[130] H. Bismuth,et al. Hepatic colorectal metastases: methods of improving resectability. , 2004, The Surgical clinics of North America.
[131] T. Okusaka,et al. Phase II Trial of Intra-Arterial Chemotherapy using a Novel Lipophilic Platinum Derivative (SM-11355) in Patients with Hepatocellular Carcinoma , 2004, Investigational New Drugs.
[132] Zhao-You Tang,et al. Randomized controlled trial of screening for hepatocellular carcinoma , 2004, Journal of Cancer Research and Clinical Oncology.
[133] M. Soulen,et al. Chemoembolization of liver metastasis from breast carcinoma. , 2004, Journal of vascular and interventional radiology : JVIR.
[134] W. Tso,et al. Factors predictive of 5‐year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma , 2003, The British journal of surgery.
[135] Luigi Solbiati,et al. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. , 2003, Radiology.
[136] J. Bruix,et al. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival , 2003, Hepatology.
[137] R. Virmani,et al. Pathologic evaluation of a spherical polyvinyl alcohol embolic agent in a porcine renal model. , 2003, Journal of vascular and interventional radiology : JVIR.
[138] Pietro Andreone,et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. , 2002, Radiology.
[139] John Wong,et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma , 2002, Hepatology.
[140] B. Chauffert,et al. Increased cytotoxicity and stability of Lipiodol-pirarubicin emulsion compared to classical doxorubicin-Lipiodol: potential advantage for chemoembolization of unresectable hepatocellular carcinoma , 2001, Anti-cancer drugs.
[141] L Pagliaro,et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.
[142] R. Shlansky-Goldberg,et al. Sarcomas metastatic to the liver: response and survival after cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol chemoembolization. , 2001, Journal of vascular and interventional radiology : JVIR.
[143] G. Gerunda,et al. Role of transarterial chemoembolization before liver resection for hepatocarcinoma , 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[144] J. Bruix,et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma , 2000, Hepatology.
[145] P. Bastian,et al. Chemo-embolization of experimental liver metastases. Part I: distribution of biodegradable microspheres of different sizes in an animal model for the locoregional therapy. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[146] A. Benson,et al. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature , 1998, Cancer.
[147] D. Guyader,et al. Prospective randomized trial of chemoembolization versus intra‐arterial injection of 131I‐labeled–iodized oil in the treatment of hepatocellular carcinoma , 1997, Hepatology.
[148] M. C. Han,et al. An experimental study of embolic effect according to infusion rate and concentration of suspension in transarterial particulate embolization. , 1997, Investigative radiology.
[149] J. Dufaux,et al. Quantification of tumor uptake of iodized oils and emulsions of iodized oils: experimental study. , 1996, Radiology.
[150] J. Bruix,et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. , 1996, Gastroenterology.
[151] V. Mazzaferro,et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.
[152] J. Dufaux,et al. Circulatory alterations induced by intra-arterial injection of iodized oil and emulsions of iodized oil and doxorubicin: experimental study. , 1995, Radiology.
[153] G. Idéo,et al. Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: A multivariate analysis of prognostic factors , 1994, Hepatology.
[154] S Sawada,et al. Transcatheter oily chemoembolization of hepatocellular carcinoma. , 1989, Radiology.
[155] R. Yamada,et al. Hepatic artery embolization in 120 patients with unresectable hepatoma. , 1983, Radiology.
[156] R. Yamada,et al. Hepatic artery embolization in 32 patients with unresectable hepatoma. , 1980, Osaka city medical journal.